ProfileGDS5678 / 1456753_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 74% 74% 73% 74% 75% 75% 75% 75% 74% 74% 73% 76% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.8502974
GSM967853U87-EV human glioblastoma xenograft - Control 24.851974
GSM967854U87-EV human glioblastoma xenograft - Control 34.8540174
GSM967855U87-EV human glioblastoma xenograft - Control 44.7970673
GSM967856U87-EV human glioblastoma xenograft - Control 54.8994174
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8241975
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8681575
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.944175
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.9394975
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.8069474
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.8357174
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.6715673
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.0600376
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.84274